AbbVie Inc.
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Elahere (mirvetuximab soravtansine) by Year
Elahere (mirvetuximab soravtansine) — U.S. net revenues ($M) ($M)
AbbVie Elahere (mirvetuximab soravtansine): $607M in FY2025, up 27.3% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-20) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Elahere (mirvetuximab soravtansine) — U.S. net revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 607 | +27.3% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 477 | – | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 0 | – | Form 10-K (filed 2026-02-20) ↗ |
| FY2022 | Dec 31, 2022 | 0 | – | Form 10-K (filed 2025-02-14) ↗ |
Breakdown
What makes up elahere (mirvetuximab soravtansine)
Cite this data
StockData. (2026). AbbVie Elahere (mirvetuximab soravtansine) ($M), annual FY2022–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/elahere-us
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.